Ultragenyx Announces Results From Phase 1/2 Study Involving KRN23 In X-Linked Hypophosphatemia In Adults

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.